F. A. Scaraggi

657 total citations
17 papers, 505 citations indexed

About

F. A. Scaraggi is a scholar working on Hematology, Genetics and Epidemiology. According to data from OpenAlex, F. A. Scaraggi has authored 17 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 3 papers in Genetics and 2 papers in Epidemiology. Recurrent topics in F. A. Scaraggi's work include Hemophilia Treatment and Research (8 papers), Blood Coagulation and Thrombosis Mechanisms (7 papers) and Platelet Disorders and Treatments (6 papers). F. A. Scaraggi is often cited by papers focused on Hemophilia Treatment and Research (8 papers), Blood Coagulation and Thrombosis Mechanisms (7 papers) and Platelet Disorders and Treatments (6 papers). F. A. Scaraggi collaborates with scholars based in Italy, Spain and United States. F. A. Scaraggi's co-authors include Angiola Rocino, Pier Mannuccio Mannucci, Massimo Morfini, Maria Elisa Mancuso, Elena Santagostino, Giuseppe Mancuso, A. Gringeri, F. Baudo, Elena Santagostino and Renato Marino and has published in prestigious journals such as Circulation, Thrombosis and Haemostasis and Metabolism.

In The Last Decade

F. A. Scaraggi

16 papers receiving 479 citations

Peers

Countries citing papers authored by F. A. Scaraggi

Since Specialization

Citations

This map shows the geographic impact of F. A. Scaraggi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. A. Scaraggi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. A. Scaraggi more than expected).

Fields of papers citing papers by F. A. Scaraggi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. A. Scaraggi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. A. Scaraggi. The network helps show where F. A. Scaraggi may publish in the future.

Co-authorship network of co-authors of F. A. Scaraggi

This figure shows the co-authorship network connecting the top 25 collaborators of F. A. Scaraggi. A scholar is included among the top collaborators of F. A. Scaraggi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. A. Scaraggi. F. A. Scaraggi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Inhibitors in haemophilia B: the Italian experience 2013 ·Haemophilia ·Giancarlo Castaman, Elisa Bonetti, M Messina, Massimo Morfini, Angiola Rocino, F. A. Scaraggi, Giuseppe Tagariello	24
2	Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI‐mediated inhibition of fibrinolysis 2012 ·Journal of Thrombosis and Haemostasis ·(unknown), (unknown), (unknown), F. A. Scaraggi, Francesca Di Serio, Barry Woodhams, N. Semeraro, Mario Colucci	19
3	Factor XI deficiency: two novel mutations in asymptomatic Italian patients 2010 ·Haemophilia ·(unknown), (unknown), Filomena Cappucci, Daniela Pisanelli, Giovanni Luca Tiscia, Pellegrino Musto, F. A. Scaraggi, Raffaele Ivan Cincione, Maurizio Margaglione, Elvira Grandone	3
4	Immune Tolerance Induction (ITI) with FVIII/VWF concentrate in Italian haemophiliacs with previous unsuccessful ITI and/or negative predictors of ITI response. 2008 ·Nova Science Publishers (Nova Science Publishers, Inc.) ·(unknown), Chiara Biasoli, (unknown), Elena Santagostino, (unknown), (unknown), F. A. Scaraggi, Giuseppe Mancuso	1
5	Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres 2007 ·Haemophilia ·Massimo Morfini, G. Auerswald, Rainer Kobelt, G Rivolta, Javier Rodríguez-Martorell, F. A. Scaraggi, Carmen Altisent, Jan Blatný, (unknown), Valentina Rossi	63
6	Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma‐derived solvent‐detergent factor VIII concentrate 2006 ·Haemophilia ·A. Gringeri, Mara Silvia Monzini, Giuseppe Tagariello, F. A. Scaraggi, Pier Mannuccio Mannucci, (unknown)	31
7	A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors 2006 ·Journal of Thrombosis and Haemostasis ·Elena Santagostino, Maria Elisa Mancuso, Angiola Rocino, Giuseppe Mancuso, F. A. Scaraggi, Pier Mannuccio Mannucci	133
8	Patients With Type 3 Severe von Willebrand Disease Are Not Protected Against Atherosclerosis 2004 ·Circulation ·A. Šrámek, Paolo Bucciarelli, Augusto B. Federici, Pier Mannuccio Mannucci, Vincenzo De Rosa, Giancarlo Castaman, Massimo Morfini, Maria Gabriella Mazzucconi, Angiola Rocino, M. Schiavoni, F. A. Scaraggi, J.H.C. Reiber, Frits R. Rosendaal	40
9	Severe venous thromboembolism in a young man with Klinefelter's syndrome and heterozygosis for both G20210A prothrombin and factor V Leiden mutations 2003 ·Blood Coagulation & Fibrinolysis ·Mario Lapecorella, Renato Marino, Giovanni De Pergola, F. A. Scaraggi, (unknown), V. De Mitrio	24
10	Short-term effects of raloxifene on the main anti-coagulant systems in postmenopausal women 2003 ·Journal of Thrombosis and Haemostasis ·Ronald V. Marino, Ettore Cicinelli, F. A. Scaraggi, Pietro Galantino, Mario Lapecorella, V. De Mitrio	2
11	Relationship between Factor VII Activity and Clinical Efficacy of Recombinant Factor VIIa Given by Continuous Infusion to Patients with Factor VIII Inhibitors 2001 ·Thrombosis and Haemostasis ·Massimo Morfini, Angiola Rocino, F. Baudo, F. A. Scaraggi, A. Gringeri, Elena Santagostino	83
12	Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor 1999 ·Blood Coagulation & Fibrinolysis ·F. A. Scaraggi, (unknown), Renato Marino, (unknown), (unknown), (unknown), O Schiraldi	10
13	Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women 1999 ·Metabolism ·V. De Mitrio, Giovanni De Pergola, Roberto Vettor, Renato Marino, Marcello Sciaraffia, Claudio Pagano, F. A. Scaraggi, Luigi Di Lorenzo, R Giorgino	33
14	Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation 1999 ·Blood Coagulation & Fibrinolysis ·V. De Mitrio, Renato Marino, F. A. Scaraggi, (unknown), (unknown), (unknown), (unknown), (unknown), O Schiraldi	19
15	The prevalence of hepatitis C virus types in patients of the same geographic area, according to the source of infection and liver disease 1997 ·Clinical and Diagnostic Virology ·Rodolfo Sacco, A. Randone, Diego Flichman, Filippo Oliveri, P. Colombatto, F. A. Scaraggi, Ferruccio Bonino, O Schiraldi, Maurizia Rossana Brunetto	4
16	Long‐term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients 1996 ·Haemophilia ·P Dentico, N. Ciavarella, F. A. Scaraggi, Mario Schiavoni, Anna Rita Volpe, Antonio Fasano, (unknown), (unknown)	15
17	Defibrotide in the treatment of Raynaud's phenomenon in patients with progressive systemic sclerosis or essential mixed cryoglobulinemia 1993 ·Current Therapeutic Research ·Giuseppe Ranieri, V. De Mitrio, (unknown), F. A. Scaraggi, (unknown), Franco Dammacco	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact